Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Stoke Therapeutics (NASDAQ:STOK), Biogen (NASDAQ:BIIB)

QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 2, 2025-

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Stoke Therapeutics (NASDAQ:STOK), Biogen (NASDAQ:BIIB)

CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia. Zorevunersen is an…